.png){kind=icon}
返回
Y
Yusuf Yazıcı
nyu langone medical center
52H指数
416论文数
1.0W被引数
收录论文 127
发表时间
.png){kind=icon}
Correspondence on 'Real-life use of the PEXIVAS reduced- dose glucocorticoid regimen in granulomatosis with polyangiitis and microscopic polyangiitis' by Nagle et al关于Nagle等人“Real-life use of the PEXIVAS reduced-dose glucocorticoid regimen in granulomatosis with polyangiitis and microscopic polyangiitis”的通信.png)
PREAI
.png){kind=icon}
分享.png){kind=icon}
收藏A Phase 3, 28-week, multicentre, randomised, double-blind, placebo-controlled trial (OA-10) to evaluate the efficacy and safety of a single injection of lorecivivint in the target knee joint of moderately to severely symptomatic osteoarthritis patients一项为期28周的III期、多中心、随机、双盲、安慰剂对照试验（OA-10），旨在评估中度至重度症状性骨关节炎患者靶膝关节单次注射lorecivivint的疗效和安全性。
PREAI
分享收藏
A methodologic problem and a conceptual issue related to the new 2022 antineutrophil cytoplasmic antibody- related vasculitis criteria sets: comment on criteria sets approved by the American College of Rheumatology Board of Directors and the European Alliance of Associations for Rheumatology Executive Committee.png)
ARTHRITIS & RHEUMATOLOGY
ARTHRITIS & RHEUMATOLOGYIF10.9
PREAI
分享收藏
分享收藏